デフォルト表紙
市場調査レポート
商品コード
1265663

オンコロジーベースのIn-Vivo CROの世界市場

Oncology Based In-Vivo CRO

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 93 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
オンコロジーベースのIn-Vivo CROの世界市場
出版日: 2023年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 93 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

オンコロジーベースのIn-Vivo CROの世界市場は2030年に22億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に11億米ドルと推定されるオンコロジーベースのIn-Vivo CROの世界市場は、2030年までに22億米ドルの改定規模に達し、2022年から2030年にかけてCAGR8.7%で成長すると予測しています。本レポートで分析したセグメントの1つである固形がんは、CAGR8.7%を記録し、分析期間終了時には11億米ドルに達すると予測されます。パンデミック後の回復を考慮し、血液がん分野の成長は、今後8年間のCAGRを7.2%に修正しました。

米国市場は3億3,130万米ドル、中国はCAGR8.2%で成長すると予測される

米国のオンコロジーベースのIn-Vivo CRO市場は、2022年に3億3,130万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが8.2%となり、2030年には3億8,350万米ドルの市場規模に達すると予測されます。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ8.1%と6.9%の成長が予測されています。欧州では、ドイツがCAGR約6.9%で成長すると予測されています。

調査対象企業の例

  • Champion Oncology, Inc.
  • Charles River Laboratory
  • Covance
  • Crown Bioscience
  • Eurofins Scientific
  • EVOTEC
  • ICON Plc
  • Living Tumor Laboratory
  • MI Bioresearch, Inc.
  • Taconic Biosciences
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xentech

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP22417

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Oncology Based In-Vivo CRO Market to Reach $2.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Oncology Based In-Vivo CRO estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$2.2 Billion by 2030, growing at aCAGR of 8.7% over the period 2022-2030. Solid Tumors, one of the segments analyzed in the report, is projected to record 8.7% CAGR and reach US$1.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Blood Cancer segment is readjusted to a revised 7.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $331.3 Million, While China is Forecast to Grow at 8.2% CAGR

The Oncology Based In-Vivo CRO market in the U.S. is estimated at US$331.3 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$383.5 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 6.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Select Competitors (Total 42 Featured) -

  • Champion Oncology, Inc.
  • Charles River Laboratory
  • Covance
  • Crown Bioscience
  • Eurofins Scientific
  • EVOTEC
  • ICON Plc
  • Living Tumor Laboratory
  • MI Bioresearch, Inc.
  • Taconic Biosciences
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xentech

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Oncology Based In-Vivo CRO - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Oncology Based In-Vivo CRO Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • JAPAN
    • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • CHINA
    • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: China 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • EUROPE
    • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • FRANCE
    • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: France 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • GERMANY
    • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Rest of Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Rest of Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Asia-Pacific Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Asia-Pacific 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Rest of World Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Rest of World 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2023 & 2030

IV. COMPETITION